title: Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system.
abstract: The lateral septum (LS) is a limbic brain region that receives serotonergic projections from raphe neurons and participates in the modulation of stress responses and affective states. The present study determined whether mineralocorticoid receptors (MRs) and/or glucocorticoid receptors (GRs) located in the LS interact with the serotonergic system in the regulation of depressive-like behavior of rats subjected to the forced swimming test (FST). We also studied the effect of corticosterone release induced by the FST on MR- and GR-mRNA expression in the LS. Specifically, we studied the antidepressant-like effects of spironolactone (a MR antagonist), mifepristone (a GR antagonist), and the antidepressant clomipramine (CMI) administered directly into the LS. In addition, spironolactone and CMI actions were studied in animals with serotonergic depletion induced by dl-p-chlorophenylalanine (pCPA). Finally, adrenalectomized and Sham-operated rats were subjected to the FST to determine MR- and GR-mRNA expression in the LS at different post-FST intervals. The results showed that intraseptal injection of spironolactone, but not mifepristone induced antidepressant-like actions in the FST; this effect was blocked by pCPA treatment. CMI and spironolactone increased 5-HT concentrations in the LS of rats subjected to the FST. Increases in corticosterone release, induced by the FST, correlated with a decrease in MR-mRNA expression in the LS; no correlation was found with GR-mRNA expression. In conclusion, MRs in the lateral septum, but not GRs, participate in the regulation of depressive-like behavior of animals subjected to the FST. Both serotonin and corticosterone play an important role in MR actions in the LS.
authors.affiliation: Dept. CINVESTAV-IPN, Sede Sur, Calzada de los Tenorios No. 235, Col. Granjas Coapa, C.P. 14330, México, D.F., Mexico. cm_qfb@msn.com
authors.forename: Christian Roberto
authors.initials: CR
authors.lastname: Mostalac-Preciado
authors.forename: Patricia
authors.initials: P
authors.lastname: de Gortari
authors.forename: Carolina
authors.initials: C
authors.lastname: López-Rubalcava
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D002997:Clomipramine / Q000008:administration & dosage / Q000494:pharmacology*; D003345:Corticosterone / Q000378:metabolism; D004347:Drug Interactions; D010134:Fenclonine / Q000494:pharmacology; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D046353:Immobility Response, Tonic / Q000187:drug effects; D008297:Male; D008845:Microinjections; D015735:Mifepristone / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000451:Mineralocorticoid Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D020665:Septum of Brain / Q000187:drug effects* / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D013148:Spironolactone / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
chemical_list: D000928:Antidepressive Agents; D000451:Mineralocorticoid Receptor Antagonists; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D015735:Mifepristone; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D002997:Clomipramine; D010134:Fenclonine; D003345:Corticosterone